IFNG and Alzheimer disease: Intracutaneous injection of C5aRA directly prevented the binding of C5a to C5aR on mast cells, then decreased the skin-fold thickness, numbers of infiltrating leukocytes and mast cells levels of IL-4, IFN-γ, histamine and IgE, thereby inhibiting the symptoms of AD.